Evidence map›Paper›PMID 34001372›Full record

ArticleBiological psychiatry2021

RETRACTED: Remission of Subacute Psychosis in a COVID-19 Patient With an Antineuronal Autoantibody After Treatment With Intravenous Immunoglobulin.

Lindsay S McAlpine, Brooke Lifland, Joseph R Check, Gustavo A Angarita, Thomas T Ngo, Samuel J Pleasure, Michael R Wilson, Serena S Spudich, Shelli F Farhadian, Christopher M Bartley

RetractedAbstract readLetterRetracted Publication
In one paragraph

Article in Biological psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. COVID-19-induced new-onset psychosis: a case report.Psychiatry research case reports · 2022
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. COVID-19 and Psychotic Symptoms: the View from Psychiatric Immunology.Current behavioral neuroscience reports · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lindsay S McAlpineDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Brooke LiflandDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Joseph R CheckDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Gustavo A AngaritaDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Thomas T NgoWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, California; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California.
Samuel J PleasureWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, California; Department of Neurology, University of California, San Francisco, San Francisco, California.
Michael R WilsonWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, California; Department of Neurology, University of California, San Francisco, San Francisco, California.
Serena S SpudichDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Shelli F FarhadianSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
Christopher M BartleyWeill Institute for Neurosciences, University of California, San Francisco, San Francisco, California; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, California; Hanna H. Gray Fellowship Program, Howard Hughes Medical Institute, Chevy Chase, Maryland.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
PET IMAGING OF SYNAPTIC DENSITY COMBINED WITH NEUROIMMUNOLOGIC MEASURES TO REVEAL MECHANISMS OF HIV NEUROPATHOGENESIS DURING ARTR01MH125396 · NIMH · YALE UNIVERSITY · PI SPUDICH, SERENA S · 2020 to 2024
$4.7M
Autoimmune Encephalitis - Ataxia and Psychiatric Disease: Identifying and Characterizing Novel Antibody TargetsR01MH122471 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPH L. DERISI, SAMUEL JEREMY PLEASURE · 2020 to 2026
$4.7M
Viral and immune-mediated CNS pathology during SARS-CoV-2 infectionR01AI157488 · NIAID · YALE UNIVERSITY · PI FARHADIAN, SHELLI, IWASAKI, AKIKO · 2020 to 2024
$4.7M
NeuroCovid Autoantibodies: Establishing a research pipelineR01NS118995 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PLEASURE, SAMUEL JEREMY · 2020 to 2024
$2.3M
Yale Clinical and Epidemiology Research in Neurology (CERN) Training ProgramT32NS105583 · NINDS · YALE UNIVERSITY · PI LICHTMAN, JUDITH H, SPUDICH, SERENA S · 2019 to 2023
$1.1M
Next-Generation Diagnostics for Acute EncephalitisK08NS096117 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WILSON, MICHAEL R · 2017 to 2021
$999k
Understanding the cellular basis for persistent immune activation in the central nervous system during virologically suppressed HIVK23MH118999 · NIMH · YALE UNIVERSITY · PI FARHADIAN, SHELLI · 2018 to 2021
$770k
Single cell RNAseq of CSF to Dissect CNS Cellular Perturbations in Long-term Treated HIVR21MH118109 · NIMH · YALE UNIVERSITY · PI SPUDICH, SERENA S · 2018 to 2019
$461k
NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI157488NIMH NIH HHS K23 MH118999NIMH NIH HHS R01 MH122471NIMH NIH HHS R01 MH125396NIMH NIH HHS R21 MH118109NINDS NIH HHS K08 NS096117NINDS NIH HHS R01 NS118995NINDS NIH HHS T32 NS105583
6 · The paper itself

Abstract

Retraction notice to: “Remission of Subacute Psychosis in a COVID-19 Patient With an Antineuronal Autoantibody After Treatment With Intravenous Immunoglobulin” by Lindsay S. McAlpine, Brooke Lifland, Joseph R. Check, Gustavo A. Angarita, Thomas T. Ngo, Samuel J. Pleasure, Michael R. Wilson, Serena S. Spudich, Shelli F. Farhadian, and Christopher M. Bartley (Biol Psychiatry 2021; 90:e23-e26); https://doi.org/10.1016/j.biopsych.2021.03.033. This article has been retracted at the request of corresponding author Christopher Bartley, with agreement from all authors and with approval from Biological Psychiatry Editor John H. Krystal, M.D. See Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). After this article was published, the authors determined that two cerebrospinal fluid (CSF) samples were inadvertently confused, resulting in publication of the wrong COVID-19 patient’s immunostaining data. The authors determined that the two CSF samples came from COVID-19 patients with sequential case identifiers (i.e., one identifier ended in a “5” and the other in a “6”). To determine whether the published immunostaining results were produced by CSF from another COVID-19 patient, the authors reperformed the mouse brain immunostaining experiments using additional aliquots of stored CSF from the two research participants in question, as well as with the remaining CSF that had been used in the publication. After repeating the immunostaining with these CSF samples, two blinded raters were able to state unequivocally that the CSF samples from the two COVID-19 patients had been confused. Therefore, while the clinical features of the case report are accurate and unaffected, the research data belong to another COVID-19 research participant, not the one described in the published case report. The authors voluntarily informed the Journal of this honest error upon its discovery. All authors agree to retract this paper and sincerely apologize for having allowed the incorrect images to be published with this case report. To avoid misinterpretation of the research findings, both the editors and authors concur that the only proper course of action was to retract this version of the paper. However, this COVID-19 psychosis case remains of clinical interest because of the patient’s clear response to immunotherapy. Therefore, the authors are revising the paper, which the Journal will consider further for publication.

Indexed as

COVID-19Psychotic DisordersAutoantibodiesHumansImmunoglobulins, IntravenousSARS-CoV-2AutoantibodiesImmunoglobulins, Intravenous

Identifiers

PMID34001372
PMCPMC8041149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.